Protecting Your Kidneys and More: Scientists Identify New Benefits of Semaglutide and Ozempic

GLP-1 agonists substantially slowed kidney deterioration and failure, independent of diabetes status. The most extensive and thorough analysis of glucagon-like peptide-1 (GLP-1) receptor agonists has revealed significant benefits for kidney and cardiovascular outcomes in individuals with and without diabetes. The findings were published in The Lancet Diabetes & Endocrinology. Initially designed to treat diabetes, GLP-1 [...]

from SciTechDaily https://ift.tt/rTejV5u